KONINKLIJKE PHILIPS NV (PHI1.DE) Stock Fundamental Analysis
FRA:PHI1 - Deutsche Boerse Ag - NL0000009538 - Common Stock - Currency: EUR
We assign a fundamental rating of 3 out of 10 to PHI1. PHI1 was compared to 57 industry peers in the Health Care Equipment & Supplies industry. PHI1 has a bad profitability rating. Also its financial health evaluation is rather negative. PHI1 has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
PHI1 had positive earnings in the past year.
The reported net income has been mixed in the past 5 years: PHI1 reported negative net income in multiple years.
Of the past 5 years PHI1 4 years had a positive operating cash flow.
1.2 Ratios
PHI1 has a Return On Assets (1.37%) which is in line with its industry peers.
PHI1 has a Return On Equity (3.19%) which is in line with its industry peers.
PHI1 has a Return On Invested Capital of 3.34%. This is in the lower half of the industry: PHI1 underperforms 61.40% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.37% | ||
| ROE | 3.19% | ||
| ROIC | 3.34% |
ROA(3y)-3.08%
ROA(5y)1.15%
ROE(3y)-7.29%
ROE(5y)2.23%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 2.07%, PHI1 is in line with its industry, outperforming 43.86% of the companies in the same industry.
PHI1's Operating Margin of 5.39% is on the low side compared to the rest of the industry. PHI1 is outperformed by 63.16% of its industry peers.
In the last couple of years the Operating Margin of PHI1 has declined.
PHI1 has a worse Gross Margin (43.42%) than 68.42% of its industry peers.
PHI1's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.39% | ||
| PM (TTM) | 2.07% | ||
| GM | 43.42% |
OM growth 3Y-1.59%
OM growth 5Y-8.09%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.71%
GM growth 5Y1.08%
2. Health
2.1 Basic Checks
PHI1 has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, PHI1 has less shares outstanding
Compared to 5 years ago, PHI1 has more shares outstanding
PHI1 has a worse debt/assets ratio than last year.
2.2 Solvency
PHI1 has an Altman-Z score of 1.83. This is not the best score and indicates that PHI1 is in the grey zone with still only limited risk for bankruptcy at the moment.
PHI1's Altman-Z score of 1.83 is in line compared to the rest of the industry. PHI1 outperforms 43.86% of its industry peers.
PHI1 has a Debt/Equity ratio of 0.60. This is a neutral value indicating PHI1 is somewhat dependend on debt financing.
PHI1 has a Debt to Equity ratio of 0.60. This is in the lower half of the industry: PHI1 underperforms 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.6 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.83 |
ROIC/WACC0.55
WACC6.1%
2.3 Liquidity
PHI1 has a Current Ratio of 1.28. This is a normal value and indicates that PHI1 is financially healthy and should not expect problems in meeting its short term obligations.
PHI1's Current ratio of 1.28 is on the low side compared to the rest of the industry. PHI1 is outperformed by 66.67% of its industry peers.
PHI1 has a Quick Ratio of 1.28. This is a bad value and indicates that PHI1 is not financially healthy enough and could expect problems in meeting its short term obligations.
PHI1's Quick ratio of 0.79 is on the low side compared to the rest of the industry. PHI1 is outperformed by 68.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.28 | ||
| Quick Ratio | 0.79 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 7.45% over the past year.
PHI1 shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -7.17% yearly.
The Revenue has decreased by -0.89% in the past year.
PHI1 shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.00% yearly.
EPS 1Y (TTM)7.45%
EPS 3Y-5.66%
EPS 5Y-7.17%
EPS Q2Q%-3.85%
Revenue 1Y (TTM)-0.89%
Revenue growth 3Y1.65%
Revenue growth 5Y1%
Sales Q2Q%-0.99%
3.2 Future
Based on estimates for the next years, PHI1 will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.40% on average per year.
PHI1 is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.10% yearly.
EPS Next Y9.94%
EPS Next 2Y11.54%
EPS Next 3Y12.13%
EPS Next 5Y12.4%
Revenue Next Year1.15%
Revenue Next 2Y2.61%
Revenue Next 3Y3.12%
Revenue Next 5Y3.1%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 14.93, which indicates a correct valuation of PHI1.
Based on the Price/Earnings ratio, PHI1 is valued cheaper than 87.72% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.41, PHI1 is valued a bit cheaper.
The Price/Forward Earnings ratio is 11.95, which indicates a very decent valuation of PHI1.
Compared to the rest of the industry, the Price/Forward Earnings ratio of PHI1 indicates a rather cheap valuation: PHI1 is cheaper than 82.46% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.19, PHI1 is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.93 | ||
| Fwd PE | 11.95 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PHI1 indicates a somewhat cheap valuation: PHI1 is cheaper than 77.19% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 11.11 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as PHI1's earnings are expected to grow with 12.13% in the coming years.
PEG (NY)1.5
PEG (5Y)N/A
EPS Next 2Y11.54%
EPS Next 3Y12.13%
5. Dividend
5.1 Amount
No dividends for PHI1!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:PHI1 (7/11/2025, 7:00:00 PM)
20.6
-0.54 (-2.55%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners42.8%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap19.84B
Analysts73.08
Price Target26.42 (28.25%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)-70.49%
DP0.27%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.14%
Min EPS beat(2)-11.97%
Max EPS beat(2)22.24%
EPS beat(4)1
Avg EPS beat(4)-3.31%
Min EPS beat(4)-16.56%
Max EPS beat(4)22.24%
EPS beat(8)2
Avg EPS beat(8)-6.4%
EPS beat(12)4
Avg EPS beat(12)8.51%
EPS beat(16)5
Avg EPS beat(16)1.66%
Revenue beat(2)0
Avg Revenue beat(2)-2.5%
Min Revenue beat(2)-3.04%
Max Revenue beat(2)-1.96%
Revenue beat(4)0
Avg Revenue beat(4)-3.17%
Min Revenue beat(4)-5.22%
Max Revenue beat(4)-1.96%
Revenue beat(8)0
Avg Revenue beat(8)-3.16%
Revenue beat(12)2
Avg Revenue beat(12)-1.77%
Revenue beat(16)2
Avg Revenue beat(16)-1.84%
PT rev (1m)-2.75%
PT rev (3m)-8.86%
EPS NQ rev (1m)-6.21%
EPS NQ rev (3m)-22.91%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.31%
Revenue NQ rev (1m)-2.12%
Revenue NQ rev (3m)-5.2%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.65%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.93 | ||
| Fwd PE | 11.95 | ||
| P/S | 1.1 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.7 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.11 |
EPS(TTM)1.38
EY6.7%
EPS(NY)1.72
Fwd EY8.37%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS18.67
BVpS12.15
TBVpS-1.33
PEG (NY)1.5
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.37% | ||
| ROE | 3.19% | ||
| ROCE | 4.75% | ||
| ROIC | 3.34% | ||
| ROICexc | 3.55% | ||
| ROICexgc | 10.93% | ||
| OM | 5.39% | ||
| PM (TTM) | 2.07% | ||
| GM | 43.42% | ||
| FCFM | N/A |
ROA(3y)-3.08%
ROA(5y)1.15%
ROE(3y)-7.29%
ROE(5y)2.23%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y10.6%
ROICexcg growth 5Y-2.51%
ROICexc growth 3Y4.73%
ROICexc growth 5Y-6.98%
OM growth 3Y-1.59%
OM growth 5Y-8.09%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.71%
GM growth 5Y1.08%
F-ScoreN/A
Asset Turnover0.66
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.6 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 2.99 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.28 | ||
| Quick Ratio | 0.79 | ||
| Altman-Z | 1.83 |
F-ScoreN/A
WACC6.1%
ROIC/WACC0.55
Cap/Depr(3y)50.01%
Cap/Depr(5y)53.78%
Cap/Sales(3y)3.94%
Cap/Sales(5y)4.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.45%
EPS 3Y-5.66%
EPS 5Y-7.17%
EPS Q2Q%-3.85%
EPS Next Y9.94%
EPS Next 2Y11.54%
EPS Next 3Y12.13%
EPS Next 5Y12.4%
Revenue 1Y (TTM)-0.89%
Revenue growth 3Y1.65%
Revenue growth 5Y1%
Sales Q2Q%-0.99%
Revenue Next Year1.15%
Revenue Next 2Y2.61%
Revenue Next 3Y3.12%
Revenue Next 5Y3.1%
EBIT growth 1Y379.25%
EBIT growth 3Y0.03%
EBIT growth 5Y-7.17%
EBIT Next Year50.08%
EBIT Next 3Y20.59%
EBIT Next 5YN/A
FCF growth 1Y-45.51%
FCF growth 3Y-40.93%
FCF growth 5Y-1.73%
OCF growth 1Y-31.12%
OCF growth 3Y-32.38%
OCF growth 5Y-4.03%